Parabolic Drugs Limited announced unaudited earnings results for the quarter ended June 30, 2018. For the quarter, the company reported net sales of INR 128.5 million as compared to INR 153.3 million a year ago. Loss before exceptional items and tax was INR 117.2 million as compared to INR 121.6 million a year ago. Loss before tax was INR 117.2 million as compared to INR 121.6 million a year ago. Net loss after tax from continuing operations was INR 117.2 million as compared to INR 121.6 million a year ago. Diluted and basic loss per share were INR 1.70 as compared to INR 2.04 a year ago.